The COVID-19 Pandemic Highlights An Unmet Need To Improve Remote Assessment of Disease Activity in Rare Diseases, Juvenile-Onset Systemic Lupus Erythematosus And Juvenile Dermatomyositis

Junjie Peng  
UCL: University College London

Puja Mehta  
UCL: University College London

Ayesha Khatun  
UCL: University College London

Wing-Han Wu  
UCL: University College London

Laura Hennelly  
UCL: University College London

Georgia Doolan  
UCL: University College London

Julian Robert Henty  
St Mary's Hospital Medical School: Imperial College London Faculty of Medicine

Paul Howard  
UCL: University College London

Elizabeth C Jury  
UCL: University College London

Coziana Ciurtin  
University College London  https://orcid.org/0000-0002-8911-4113

Short Report

Keywords: pilot, survey, pandemic, COVID-19, anonymously

Posted Date: November 3rd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1021418/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Here we report the results of a pilot young patient survey which targeted patients with juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM), which explored wellbeing, resilience and general concern about the COVID-19 pandemic. The survey was completed anonymously by patients who have been approached via the automatically generated hospital data base between June-December 2020. This pilot study found that generalised concerns regarding the COVID-19 pandemic were significantly higher in females, although their self-reported disease activity scores were comparable with male respondents. Our findings highlight a need to improve remote assessments to facilitate triaging for face-to-face visits in the situation of future pandemics associated with disruption of clinical services, as well as further research in this area of young patient-reported outcomes outside hospital visits.

Background:

The impact of the COVID-19 pandemic on the delivery of healthcare for adolescents and young people should not be underestimated, even though this population is less clinically vulnerable to COVID-19 infection. Physiological, psychological and social-role changes during this period heavily influence future well-being and health. The additional consequences of disrupted access to education, work and healthcare, and social and financial stresses during the pandemic have had significant impact on mental health and well-being(1). Young people with chronic health conditions, already face a disproportionate psychosocial burden compared with their peers, and are likely to face additional worries and concerns regarding COVID-19, including heightened health-related anxiety, disrupted routines, reduced access to physical and psychosocial support(2).

As clinicians working in a specialist centre, we aimed to evaluate the impact of the COVID-19 pandemic in adolescents and young adults with juvenile-onset systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM). These are rare, complex autoimmune connective tissue disorders with a female preponderance, associated with multiple organ involvement and significant impact on quality of life. Here we report the results of a pilot survey, which explored wellbeing, resilience and concern about the COVID-19 pandemic in patients with JSLE and JDM.

Patient Cohort And Methods:

The survey was completed anonymously by patients between June-December 2020. The hospital digital database generated a complete list of patients with JDM and JSLE, who were under the care of Department for Adolescent Rheumatology at University College London Hospital in 2020. Automatic emails were sent to registered patient emails available in the database and patients of age 16 and over (who were legally able to consent at the time of inclusion in this exploratory survey) were invited to complete the survey anonymously accessed via a link to a RedCap questionnaire database. None of the patients have been approached to complete the questionnaire when attending clinics in person to
minimise the potential selection bias. The survey has been approved by the local ethics committee (Ref. 20/HRA/2565).

Results were analysed using descriptive statistics (using R). The survey (available as Supplementary file) contained questions about patient's demographics (age, ethnicity, gender), employment and education status, disease duration, age at onset, as well as well-being or resilience, using the validated mood and feeling questionnaire (MFQ)(3), resilience scale(4) and the Warwick-Edinburgh mental well-being scales(5). The patients were also required to complete a VAS 0-100 scale to rate their general concerns regarding the general impact of COVID-19 on their lives.

**Findings:**

There were 63 respondents (53 females; 10 males) who answered the survey during the recruitment period. The survey had a 47% response rate, which is not unsurprising considering that patients have not been approached in person as many of the routine clinical assessments were conducted virtually. Reflecting the significant gender bias in JSLE and the higher prevalence of JSLE compared to JDM, there was a predominance of young females completing the survey (84%). There were no significant gender differences in the disease duration, age at diagnosis, disease duration, age of responders or immunosuppressive medication according to self-reported gender (Table 1). The majority of patients were living outside London as we are a tertiary centre for adolescent and young adult rheumatology. Generalised concerns regarding the COVID-19 pandemic were significantly higher in females (p=0.007), although their self-reported disease activity scores were comparable with male respondents (p=0.205) [Table 1, Figure 1A]. The self-reported reported resilience was almost identical in young men and women (p=0.99).

Linear regression analysis, adjusted for age, ethnicity and gender demonstrated that self-reported disease activity (using a global visual analogue scale) was the strongest determinant of concerns associated with COVID-19 (p<0.0003) (Figure 1B), which was evident in both females (p= 0.003) and males (p=0.004). Longer disease duration was associated with general concerns regarding COVID-19 pandemic in males only (p=0.018). There was no association between COVID-19-associated concerns and employment and education status, or well-being or resilience, using the validated mood and feeling questionnaire (MFQ)(3), resilience scale(4) and the Warwick-Edinburgh mental well-being scales(5).

**Conclusion:**

To our knowledge, this is the first focused evaluation of the impact of the COVID-19 pandemic on patients with JSLE and JDM. Our results demonstrate that gender differences should be considered when assessing patients, and that concerns regarding COVID-19 strongly correlate with patient-reported disease activity when accounting for other confounders. We were unable to compare patient-reported and physician-assessed disease activity, given restricted access to clinic appointments during the height of the pandemic. Previous psychology research has identified gender differences in wellbeing in healthy
young people, while the most important predictors of well-being in emerging adulthood were higher self-confidence and lower negative self-evaluation, aspects that are likely to be affected by having to live with a chronic condition such as JSLE or JDM. In addition, well-being at the age of emerging adulthood is recognised as having significant impact on further psychological well-being; therefore addressing additional psychological stressors, such as general concern related to COVID-19 pandemic in young people with chronic conditions could have long term benefits.

The main limitations of this exploratory survey are related to the relatively small sample size of this single centre study, which does not allow for generalization of results, and inability to establish any causal relationship between the outcomes measured. There are still uncertainties about the outcomes of COVID-19 infection/vaccination in children and young people with chronic inflammatory conditions, despite the re-assuring signals to date; this is likely to be reflected in their general COVID-19-associated concern.

Telemedicine gained traction during the pandemic and is likely to have a more permanent place in mainstream healthcare provision hereafter. Virtual consultations are particularly relevant for continuity of routine care for rare diseases in high-risk groups, including our cohort of JSLE and JDM, as patients often have to travel considerable distances to obtain tertiary expertise and may be shielding due to inherent and iatrogenic immunocompromise. There are recognised advantages and disadvantages of care delivery via virtual consultations for young people, in addition to the challenges of suffering from a complex autoimmune condition such as JSLE and JDM which have to be taken into account when designing virtual clinical services. Our findings highlight a need to improve remote assessments to facilitate triaging for face-to-face visits, by developing standardised composite patient reported outcome measures for disease activity. Emerging digital technologies for self-assessment, monitoring and reporting of disease activity are likely to be important tools to empower young people and promote independence, as they transition to young adult services.

Abbreviations

JDM- juvenile dermatomyositis

JSLE – juvenile systemic lupus erythematosus

MFQ - mood and feeling questionnaire

VAS – visual analogue scale

Declarations

Ethical Approval and Consent to participate: The survey has been approved by the local ethics committee (Ref. 20/HRA/2565).
Consent for publication: was included in the ethical approval.

Availability of supporting data: supplementary data can be made available upon request

Competing interests: all authors declared no conflicts of interest.

Funding: This research was funded by NIHR UCLH Biomedical Research Centre (BRC525/III/CC/191350, BRC 773III/CC/101350) and Lupus UK. This work was performed within the Centre for Adolescent Rheumatology Versus Arthritis at UCL UCLH and GOSH supported by grants from Versus Arthritis (21593 and 20164). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Authors' contributions: CC designed the questionnaire with input from AK, W-HW, PM, LH, GD, PH, JH, EJ. JP performed the data analysis with input from EJ, CC. All authors contributed to data collection and reviewed the data analysis. JP, PM and CC wrote the paper. All authors reviewed and approved the final manuscript.

Acknowledgements: We would like to thank Dr. Melanie Sloan from the Department for Public Health, University of Cambridge for advice on survey questions.

Authors' information: not further relevant information.

References

1. Digital N. Mental Health of Children and Young People in England, 2020: Wave 1 follow up to the 2017 survey 2020 [Available from: https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-young-people-in-england/2020-wave-1-follow-up.

2. Serlachius A, Badawy SM, Thabrew H. Psychosocial Challenges and Opportunities for Youth With Chronic Health Conditions During the COVID-19 Pandemic. JMIR Pediatr Parent. 2020;3(2):e23057.

3. Angold A, Costello EJ, Messer SC, Pickles A. Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. International Journal of Methods in Psychiatric Research. 1995;5(4):237-49.

4. GM W. Resilience Scale - A Reliable and Valid tool to Measure Resilience 2009 [Available from: https://www.resiliencecenter.com/.

5. Warwick-Edinburgh mental well-being scales [Available from: https://warwick.ac.uk/fac/sci/med/research/platform/wemwbs/.

6. Tome G, Gaspar de Matos M, Reis M, Gomez-Baya D, Coelho F, Wiium N. Positive Youth Development and Wellbeing: Gender Differences. Front Psychol. 2021;12:641647.
7. Matud MP, Bethencourt, J.M., Ibáñez, I., Fortes D., Diaz A. Gender Differences in Psychological Well-Being in Emerging Adulthood. Applied Research Quality Life (2021).https://doi.org/10.1007/s11482-021-09943-5.

8. Arnett JJ, Zukauskiene R, Sugimura K. The new life stage of emerging adulthood at ages 18-29 years: implications for mental health. Lancet Psychiatry. 2014;1(7):569-76.

9. Deakin CT, Cornish GH, Ng KW, Faulkner N, Bolland W, Hope J, et al. Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases. Med (N Y). 2021;2(9):1093-109 e6.

10. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339-43.

11. Naja M, Wedderburn L, Ciurtin C. COVID-19 infection in children and adolescents. Br J Hosp Med (Lond). 2020;81(8):1-10.

12. Marlais M, Wlodkowski T, Vivarelli M, Pape L, Tonshoff B, Schaefer F, et al. The severity of COVID-19 in children on immunosuppressive medication. Lancet Child Adolesc Health. 2020;4(7):e17-e8.

13. Blackburn F, Butler M, Cheung CR. ‘The paediatrician will hear you now’: making virtual outpatient consultations work for children and young people. Arch Dis Child. 2020.

14. McDonagh JE, Tattersall R, Clinch J, Swan J, Foster HE, McCann L. Developmentally appropriate transitional care during the Covid-19 pandemic for young people with juvenile-onset rheumatic and musculoskeletal diseases: the rationale for a position statement. Pediatr Rheumatol Online J. 2021;19(1):136.

Tables

Table1: Patient characteristics according to self-reported gender
|                                | Female                  | Male                  | p-value |
|--------------------------------|-------------------------|-----------------------|---------|
| **Number**                     | 53                      | 10                    | -       |
| **Current age mean (IQR)**     | 22.42 (19.00-27.00)     | 22.86 (17.15-29.25)   | 0.87    |
| **Age at diagnosis years mean (IQR)** | 11.47 (9.00-14.00)   | 10.00 (8.00-11.75)    | 0.26    |
| **Disease duration; Mean (IQR)** | 10.94 (5.00-16.00)     | 12.86 (9.70-18.75)    | 0.46    |
| **Ethnicity;**                 |                         |                       |         |
| White                          | 33 (62.3%)              | 8 (80.0%)             | 0.47    |
| Non-white                      | 20 (37.7%)              | 2 (20.0%)             |         |
| **Location;**                  |                         |                       |         |
| London (%)                     | 13 (24.5%)              | 2 (20.0%)             | 1.00    |
| Other (%)                      | 40 (75.5%)              | 8 (80.0%)             |         |
| **Immunosuppressive treatment (%)** | 40 (75.4)              | 8 (80%)               | 0.97    |
| Prednisolone treatment (%)     |                         |                       |         |
| (%)                            | 22 (41.5)               | 5 (50%)               | 0.83    |
| Well-being (VAS 0-5) mean (IQR) | 3.066                   | 3.486                 | 0.27    |
| Resilience (VAS 0-7) mean (IQR) | 4.764 (3.714-5.571)  | 4.757 (3.929-6.161)   | 0.99    |
| Self-reported disease activity (VAS 0-100) mean (IQR) | 30.83 (10.00-50.00) | 17.70 (1.00-21.25) | 0.205 |
| Self-reported COVID concern (VAS 0-100) mean (IQR) | 61.77 (50.00-80.00) | 30.90 (11.25-43.75) | 0.007 |
| Still in education             |                         |                       |         |
| No                             | 27 (50.9%)              | 5 (50.0%)             | 1.00    |
| Yes                            | 26 (49.1%)              | 5 (50.0%)             |         |
| From those previously employed, currently working |                         |                       |         |
| No                             |                         |                       |         |
Legend: IQR - interquartile range; VAS – visual analogue scale.

**Figures**

**A**

- First panel - Differences in COVID concern level (VAS 1-100, 100 being the highest concern regarding health-outcomes during COVID-19 pandemic) according to gender in patients with JSLE and JDM

**B**

- Second panel - Self-reported disease activity according to gender in patients with JSLE and JDM

**Figure 1**

A First panel - Differences in COVID concern level (VAS 1-100, 100 being the highest concern regarding health-outcomes during COVID-19 pandemic) according to gender in patients with JSLE and JDM Second
panel - Differences in self-reported disease activity (VAS 1-100, 100 being the highest self-perceived disease activity) according to gender in patients with JSLE and JDM. B Linear regression analysis, adjusted for age, ethnicity and gender demonstrated that self-reported disease activity (using a global visual analogue scale) was the strongest determinant of concerns associated with COVID-19 pandemic.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Surveyblank.pdf